Accretion Nutraveda IPO: Contract Manufacturing Meets Preventive Healthcare

Accretion Nutraveda Limited is a Gujarat-based nutraceutical Contract Development and Manufacturing Organization (CDMO) engaged in manufacturing ayurvedic and nutraceutical products across multiple dosage forms. The company operates on a B2B contract manufacturing model, serving domestic and export-oriented clients. It is currently scaling operations through capacity expansion and automation.

IPO Details

Strengths and Weaknesses of Accretion Nutraveda Limited

Now let’s move forward to unfold the whole business story and their numbers

Industry Overview

The Indian pharmaceutical industry, globally recognized as the "Pharmacy of the World," ranks 3rd worldwide by production volume and 14th by value. The sector was valued at US$ 55 billion in FY25 and is projected to grow significantly to US$ 130 billion by 2030 and US$ 450 billion by 2047.India is a dominant player in the global supply chain, providing approximately 20% of global generic drug exports, with total pharmaceutical exports reaching US$ 30.38 billion in FY25. The industry comprises key segments such as Generics, Over-The-Counter (OTC) medicines, Active Pharmaceutical Ingredients (APIs), and vaccines, with India holding an 8% share in the global API market. Notably, the Contract Research and Development Manufacturing Organization (CRDMO) segment is emerging as a critical growth area, expected to double to US$ 14 billion by 2028, driven by cost efficiencies and established manufacturing infrastructure.

Growth in the Indian pharmaceutical sector is propelled by robust supply-side and demand-side drivers. On the supply side, government initiatives such as the Production Linked Incentive (PLI) scheme, with an outlay of US$ 2.04 billion, and the "China Plus One" strategy are encouraging domestic manufacturing and global supply chain diversification. Additionally, India boasts the second-highest number of USFDA-approved plants outside the US. On the demand side, rising income levels, increasing prevalence of chronic lifestyle diseases, and higher health insurance penetration through schemes like Ayushman Bharat (PM-JAY) are boosting domestic consumption. The government also aims to expand affordable healthcare access by increasing the number of Pradhan Mantri Bhartiya Janaushadhi Kendras to 25,000. Together, these factors create a favorable environment for sustained expansion in the healthcare and pharmaceutical domains.

Accretion Nutraveda Limited is a Gujarat-based nutraceutical and wellness company engaged in the manufacturing of Ayurvedic and Nutraceutical products across several dosage forms, including Tablets, Capsules, Oral liquids, Oral Powders, External Preparation and Oils. We are a healthcare focused Company specialising in contract manufacturing, serving domestic as well as export markets in various countries like Sri Lanka, Singapore and the USA. Incorporated in March 2021 and converted into a public limited company in May 2025, the company operates out of its manufacturing facility located at Sanand, Ahmedabad, a well-established pharmaceutical and nutraceutical hub. 

Accretion Nutraveda Limited operates as a healthcare-focused Contract Development and Manufacturing Organization (CDMO). The company does not sell directly to end consumers; instead, it provides specialized manufacturing services to clients across various industries for third-party brands under their respective labels. Clients typically include:

• Nutraceutical and wellness brands

• Healthcare marketers

• E-commerce-led D2C nutrition companies

• Pharma distributors expanding into nutrition supplements

Under this model, Accretion earns revenue based on per-unit manufacturing contracts, benefiting from scale efficiencies without incurring end-consumer marketing costs.

A CDMO offers a complete turnkey solution, covering product formulation and customization, raw material sourcing, blending, processing, and manufacturing, quality control and compliance, packaging and labeling. For a CDMO, Margins are driven by Volume throughput, Raw material procurement efficiency, Repeat orders from long-term clients.

Product Portfolio

The product portfolio includes tablets such as film-coated and chewable forms, intended for applications related to liver care, gynecological care, bone and joint health, and respiratory support. We also manufacture capsules, including both hard gelatin and HPMC types, directed towards liver detoxification, women’s health, and cognitive support. Our oral liquid products include syrups, suspensions, tonics, and traditional decoctions, formulated for paediatric and geriatric applications. Additionally, our Company produces traditional Ayurvedic powders, known as “churans,” for digestive health, medicated Ayurvedic oils used in musculoskeletal and dermatological treatments, and a range of external preparations including balms, ointments, creams, and gels used in pain relief, skin care, and hair care.

Revenue Model and Streams

The company earns revenue on a per-unit or batch-wise manufacturing basis, depending on product complexity, dosage form, and volume commitments from clients. Pricing typically factors in raw material costs, processing and conversion charges, quality compliance, and margin spreads, allowing partial pass-through of input cost fluctuations. Revenues are order-driven and recurring in nature, supported by repeat business from existing clients. Geographically, a significant majority of our revenue is generated within the state of Gujarat. 

Manufacturing Facility, Capacity Utilization, and Certifications

Accretion Nutraveda Limited operates a specialized manufacturing facility located in Sanand, Ahmedabad, Gujarat, which is situated on leased premises with a total built-up area of approximately 1,000 square meters (approx. 10,763 sq. ft.). The unit holds a robust suite of national and international accreditations, including WHO-GMP, ISO 9001:2015, ISO 45001:2018, FSSC 22000, and Halal certification, alongside licenses from FSSAI and the Gujarat Food & Drugs Control Administration.

In terms of operational performance, the company has witnessed a significant surge in capacity utilization across its primary product lines. For the period ended September 30, 2025, utilization rates reached 84.09% for capsules (up from 19.62% in FY 2024), 79.78% for oral liquids, and 51.42% for tablets. Furthermore, the company significantly expanded its installed capacity for External Preparations from 3.15 million units in FY 2025 to 10.65 million units for the period ended September 2025, achieving a utilization rate of 70.90% on this expanded capacity. To address growing demand and capacity constraints, the company has entered into a lease agreement for an adjacent plot to establish a new manufacturing unit.

Management + Promoters

The Company has six individual Promoters who collectively hold 92.48% of the pre-issue paid-up equity share capital.

 Executive Directors (Promoters)

• Mr. Mayur Popatlal Sojitra (Managing Director): He holds a Bachelor of Pharmacy and an MBA in International Business from the University of Greenwich, London. With over 12 years of experience, he oversees the company's sales and marketing verticals, engaging directly with clients to expand market share.

• Mr. Ankurkumar Shantilal Patel (Whole Time Director): He holds a Master of Pharmacy (Ayurved) and has over 16 years of experience, having worked with entities like Vasu Healthcare, Emami Limited, and Sri Sri Ayurveda Trust. He focuses on research, innovation, and operational management.

• Mr. Paraskumar Vinubhai Parmar (CFO & Executive Director): He holds a Master of Arts in International Business from the University of Greenwich, London. He has over a decade of experience in financial management and strategic planning and is responsible for the finance-related functions of the company,

 Non-Executive Directors (Promoters)

• Mr. Harshad Nanubhai Rathod (Chairman & Non-Executive Director): He holds a B.Pharm and an MBA. With over 12 years of experience spanning product development and regulatory affairs, he also serves as a director in the group company, Accretion Pharmaceuticals Ltd,.

• Mr. Hardik Mukundbhai Prajapati: He holds a Masters of Pharmacy and has over 12 years of experience in pharmaceutical production processes.

• Mr. Vivek Ashok Kumar Patel: He holds an MBA in Pharmaceutical Industry Management and has over 14 years of diversified experience in production and marketing, including a tenure at Merck Ltd.

While there are no outstanding criminal proceedings or actions by statutory authorities filed directly against Accretion Nutraveda Limited (the Issuer), there are significant legal matters involving its Promoters and Group Companies.

• Litigation Involving Promoters and Directors:
  
  

  • Juvenile Justice Case: Promoters Mr. Mayur Popatlal Sojitra and Mr. Harshad Nanubhai Rathod were named in a criminal case regarding alleged violations of the Juvenile Justice Act (related to child labor) arising from a police investigation into a missing minor found at the premises. The Additional Chief Judicial Magistrate disposed of the case in May 2024 due to a lack of jurisdiction, directing it to be transferred to a Children's Court. As of the date of the prospectus, no new summons had been received regarding the transferred matter.

  • Drug Quality Proceedings: A criminal complaint was filed by the Assistant Drugs Controller, Mysuru, against Accretion Pharmaceuticals and its partners (Promoters Mr. Harshad Nanubhai Rathod and Mr. Vivek A. Patel) alleging that a batch of tablets (“Dolclox-SP”) was "not of standard quality." The promoters have challenged this in the High Court of Karnataka, citing procedural lapses in testing timelines. The High Court stayed further proceedings in the lower court until February 2, 2026.

Group Companies

Accretion Nutraveda Limited has identified two entities as Group Companies based on related party transactions and materiality. These companies operate within the broader healthcare and pharmaceutical sector, sharing common promoters and business interests with the Issuer.

• Accretion Pharmaceuticals Limited: This entity has a long-standing history with the promoters. Originally established as a partnership firm named "M/s Accretion Pharmaceuticals" in 2012 by promoters Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra, and Mr. Hardik Mukundbhai Prajapati, it was converted into a public limited company in 2023. The company is currently listed on the NSE Emerge platform. Its business operations are quite similar to the Issuer, as it is engaged in the manufacturing and marketing of a wide range of pharmaceutical dosage forms including tablets, capsules, oral liquids, and external preparations like ointments and gels.

• Accresha Lifecare Private Limited: Incorporated on November 24, 2021, this company focuses on the export market. Its primary business activities involve the manufacturing and exporting of pharmaceutical finished formulations and semi-finished products, with a stated focus on making innovative generic medicines available at affordable costs.

The company has demonstrated strong revenue and profitability growth, with revenue from operations increasing from ₹2.91 cr in FY23 to ₹16.00 cr in FY25, reflecting rapid scale-up of operations and improved client traction. This growth has translated into healthy operating performance, with EBITDA margins consistently above 22%, indicating efficient cost control and favorable product mix in a contract manufacturing-led business. PAT has grown sharply from ₹0.28 cr in FY23 to ₹2.61 cr in FY25, with PAT margins stabilizing at ~16%, highlighting operating leverage as volumes scale.

However, cash flow generation remains a key area of concern. Despite rising profitability, cash flow from operations (CFO) has turned negative in FY25, largely due to a sharp increase in working capital intensity. Working capital has expanded from ₹0.76 cr in FY23 to ₹7.21 cr in FY25, driven by elevated inventory and receivable levels as the company scales its order book.

Inventory days have remained structurally high, increasing to 278 days in FY25, reflecting raw material stocking, wider product mix, and readiness to service larger orders. Receivable days have also increased to 74 days in FY25, consistent with B2B credit terms extended to customers. Together, this has resulted in significant cash being locked in operations, a common feature of fast-growing SME contract manufacturers.

Debt levels have risen in line with business expansion, from ₹1.97 cr in FY23 to ₹3.85 cr in FY25, largely to support incremental working capital requirements. While leverage remains moderate, the increasing dependence on debt to fund operating assets underscores the importance of improved cash conversion going forward.

Overall, the financial profile reflects a high-growth, high-margin manufacturing business transitioning into a scale phase, where profitability has outpaced cash flows. Sustained improvement in inventory turnover, receivable collection, and working capital discipline will be critical to translating accounting profits into operating cash flows and strengthening balance sheet quality post listing.

Peer Analysis

Purchase of Machinery for Automation in Existing Manufacturing Unit The Company intends to invest ₹4.21Cr to automate its existing facility at Plot 27, Sanand. The rationale for this investment includes:

• Operational Efficiency & Quality: The primary objective is to enhance operational efficiency, reduce reliance on manual intervention, and improve product quality and consistency.

• Cost & Resource Optimization: Automation is expected to achieve cost-effectiveness through improved resource utilization and minimized wastage.

• Meeting Demand: Advanced machinery will optimize production capacity, strengthen the company's competitive edge, and enable it to meet growing customer demand in a timely manner.

Purchase of Machinery for New Manufacturing Setup The Company plans to utilize ₹8.03 Cr to set up a new manufacturing unit at Plot 26, Sanand, which is adjacent to the existing facility. The rationale includes:

• Capacity Constraints: The existing manufacturing facility is currently operating close to its optimal capacity.

• Market Demand: There is increased demand in the nutraceuticals market, necessitating an expansion of production capabilities to support the growing scale of operations.

• Strategic Location: Locating the new unit adjacent to the existing facility allows for better operational synergy.

Funding Working Capital Requirements The Company proposes to utilize ₹5.50 Cr to fund its working capital. The rationale is driven by projected growth in operations for Fiscal 2026 and 2027, specifically:

• Production Volume: The planned expansion of production capacity to meet demand will naturally increase the inventory levels of raw materials, work-in-progress, and finished goods, thereby increasing working capital needs.

• Sales Network Expansion: The Company plans to expand into new domestic geographies and deepen engagement with corporate clients. This is expected to drive higher sales volumes on credit, resulting in an increase in trade receivables.

• Direct Exports: The strategy to expand direct export operations (which offer higher margins) requires additional inventory buffers to meet international orders and will lead to an increase in trade receivables.

• Product Portfolio Expansion: The launch of new and innovative formulations requires higher raw material procurement, testing, and stocking to ensure timely market supply.

Final Words – LMVT Framework

Leadership:

 Accretion Nutraveda is a promoter-led nutraceutical CDMO with management possessing deep operating experience across pharmaceuticals, ayurveda, and contract manufacturing. The team has demonstrated the ability to scale revenues rapidly while sustaining healthy margins, though the presence of similar group businesses makes governance discipline and capital allocation critical post listing.

Moat: 

The company’s competitive advantage stems from its role as a compliant CDMO with a diversified portfolio comprising over 72 formulations, including tablets, capsules, and external preparations. Its manufacturing infrastructure in Sanand, Gujarat, acts as a barrier to entry for unorganized players, secured by critical certifications such as WHO-GMP, ISO 9001:2015, and Halal, which enable exports to regulated markets. Furthermore, the business is fortified by long-standing relationships with clients and suppliers, ensuring repeat orders and supply chain stability without relying on formal long-term contracts.

Valuation: 

At the upper price band of ₹129 per share, the company is valued at a P/E ratio of 17.94x based on FY 2025 earnings and 13.64x based on annualized FY 2026 earnings, which is attractively priced compared to the industry average P/E of 45.14x. 

Tailwinds: 

The company operates in a favorable environment driven by the Indian pharmaceutical market's projected growth to US$ 130 billion by 2030 and the domestic market hitting US$ 57 billion by FY25. Key growth drivers include government initiatives like the Production Linked Incentive (PLI) scheme and the expansion of Jan Aushadhi Kendras, which support domestic manufacturing. Additionally, the global "China Plus One" supply chain diversification strategy and increasing consumer demand for preventive medicine and nutraceuticals provide strong momentum for the company's expansion.